GlassScriptPhysician profile
Brian K Behnke
NPI 1033679600
$2,923.18
in general payments reported to CMS, 2019-2025
35 companies · $2,498 in 2025
The $2,498 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.54 · 2024: $406 · 2025: $2,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,437 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.85 |
| Education | $177.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $335.36 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $239.97 | 2024-2025 | Saphnelo, Imfinzi, Enhertu |
| Amgen INC. | $171.12 | 2025 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.87 | 2025 | |
| Janssen Biotech, INC. | $165.36 | 2025 | Tremfya, Rybrevant |
| Sobi, INC | $151.71 | 2025 | |
| Ucb, INC. | $136.85 | 2024-2025 | Bimzelx |
| Abbvie INC. | $131.46 | 2025 | |
| Novo Nordisk INC | $118.63 | 2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Stemline Therapeutics INC. | $77.94 | 2025 | Orserdu |
| Daiichi Sankyo INC. | $75.69 | 2025 | Datroway, Enhertu |
| Merck Sharp & Dohme LLC | $57.08 | 2025 | Keytruda, Welireg, Lynparza |
| Glaxosmithkline, LLC. | $55.68 | 2025 | Benlysta, Ojjaara |
| Fresenius Kabi USA, LLC | $55.07 | 2025 | Tyenne |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $53.02 | 2025 | Tymlos |
| Iovance Biotherapeutics, INC. | $48.05 | 2025 | Amtagvi |
| Jazz Pharmaceuticals INC. | $38.16 | 2025 | |
| Karyopharm Therapeutics INC. | $33.54 | 2025 | Xpovio |
| Spectrum Pharmaceuticals INC. | $33.50 | 2025 | Rolvedon |
| Genmab U.S., INC. | $33.24 | 2025 | Epkinly |
| Servier Pharmaceuticals LLC | $31.45 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.45 | 2025 | Fruzaqla |
| Rigel Pharmaceuticals, INC. | $28.02 | 2025 | Rezlidhia, Gavreto, Tavalisse |
| Legend Biotech USA INC. | $27.94 | 2025 | Carvykti |
| Genentech USA, INC. | $27.42 | 2025 | Tecentriq |
| Incyte Corporation | $27.31 | 2025 | Jakafi |
| Puma Biotechnology, INC. | $25.90 | 2025 | |
| Scilex Pharmaceuticals INC. | $24.07 | 2025 | |
| Recordati_rare_diseases_inc. | $22.13 | 2025 | Sylvant |
| Aveo Pharmaceuticals, INC. | $20.89 | 2025 | |
| Pfizer INC. | $20.51 | 2025 | |
| Lilly USA, LLC | $19.69 | 2025 | Taltz |
| Aurinia Pharma U.S., INC. | $19.35 | 2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $14.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Behnke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.